Review in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
Frontiers in oncology · 2026
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Tonathiu RodríguezLaboratorio de Inmunidad Innata, Unidad de Investigación en Biomedicina (UBIMED), Facultad de Estudios Superiores Iztacala (FES-I), Universidad Nacional Autónoma de México (UNAM), Av. de los Barrios 1, Los Reyes Iztacala, Tlalnepantla 54090, Estado de México, Mexico.ORCID 0000-0002-5895-1648
Víctor H Salazar-CastañónLaboratorio de Inmunología Molecular, Unidad de Investigación Química Computacional, Síntesis y Farmacología en Moléculas de Interés Biológico, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México (UNAM), Batalla 5 de Mayo esquina Fuerte de Loreto, Iztapalapa 09230, Ciudad de México, Mexico.ORCID 0000-0003-3620-7858
Luis I TerrazasLaboratorio de Inmunoparasitología, Unidad de Investigación en Biomedicina (UBIMED), Facultad de Estudios Superiores Iztacala (FES-I), Universidad Nacional Autónoma de México (UNAM), Av. de los Barrios 1, Los Reyes Iztacala, Tlalnepantla 54090, Estado de México, Mexico.ORCID 0000-0003-4649-4117
Imelda Juárez-AvelarLaboratorio de Inmunidad Innata, Unidad de Investigación en Biomedicina (UBIMED), Facultad de Estudios Superiores Iztacala (FES-I), Universidad Nacional Autónoma de México (UNAM), Av. de los Barrios 1, Los Reyes Iztacala, Tlalnepantla 54090, Estado de México, Mexico.
Miriam Rodríguez-SosaLaboratorio de Inmunidad Innata, Unidad de Investigación en Biomedicina (UBIMED), Facultad de Estudios Superiores Iztacala (FES-I), Universidad Nacional Autónoma de México (UNAM), Av. de los Barrios 1, Los Reyes Iztacala, Tlalnepantla 54090, Estado de México, Mexico.ORCID 0000-0003-2911-9390
Funding
Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (DGAPA), Universidad Nacional Autónoma de México (UNAM) IN208126Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (DGAPA), Universidad Nacional Autónoma de México (UNAM) IV200425
6 · The paper itself
Abstract
Some parasitic infections promote or inhibit vascular growth in their hosts to increase parasite survival through immune evasion and tissue dissemination. This review focuses on how the most prevalent protozoan and helminth parasites in humans, such as
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Parasites as Modulators of Angiogenesis: Implications for Vascular Biology and Pathogenesis. · full record | OpenQuestion